CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: Biomarker correlates from the randomized phase-2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer

Frontiers in Oncology

Volumn 5, Issue JUN, 2015, Pages

  Lee, Jung Min ^a   Trepel, Jane B ^a   Choyke, Peter ^a   Cao, Liang ^a   Sissung, Tristan ^a   Houston, Nicole ^a   Yu, Minshu ^a   Figg, William D ^a   Turkbey, Ismail Baris ^a   Steinberg, Seth M ^a   Lee, Min Jung ^a   Percy Ivy, S ^a   Liu, Joyce F ^b   Matulonis, Ursula A ^b   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; CEC; Cediranib; IL 8; Olaparib; Ovarian cancer

Indexed keywords

CEDIRANIB; INTERLEUKIN 6; INTERLEUKIN 8; OLAPARIB; PLATINUM; POLY(ADENOSINE DIPHOSPHATE RIBOSE); VASCULOTROPIN;

ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; DRUG SENSITIVITY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALIDITY; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84934282871     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00123     Document Type: Article

References (52)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64(1):9-29. doi: 10.3322/caac.21208
2. Cannistra SA. Cancer of the ovary. N Engl J Med (2004) 351(24):2519-29. doi:10.1056/NEJMra041842
3. Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer. Ann Oncol (2010) 21(Suppl 7):vii218-22. doi:10.1093/annonc/mdq377
4. Liu JF, Cannistra SA. Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer. J Clin Oncol (2014) 32(13):1287-9. doi:10.1200/JCO.2013.54.7299
5. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 32(13):1302-8. doi:10.1200/JCO.2013.51.4489
6. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 365(26):2473-83. doi:10.1056/NEJMoa1104390
7. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol (2014) 32(30):3374-82. doi:10.1200/JCO.2014.55.7348
8. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 27(33):5601-6. doi:10.1200/JCO.2009.23.2777
9. Economopoulou M, Langer HF, Celeste A, Orlova VV, Choi EY, Ma M, et al. Histone H2AX is integral to hypoxia-driven neovascularization. Nat Med (2009) 15(5):553-8. doi:10.1038/nm.1947
10. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA (2010) 107(5):2201-6. doi:10.1073/pnas.0904783107
11. Mathews MT, Berk BC. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol (2008) 28(4):711-7. doi:10.1161/ATVBAHA.107.156406
12. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 12(9):852-61. doi:10.1016/S1470-2045(11)70214-5
13. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 15(11):1207-14. doi:10.1016/S1470-2045(14)70391-2
14. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol (2014) 25(1):32-40. doi:10.1093/annonc/mdt384
15. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 72(21):5588-99. doi:10.1158/0008-5472.CAN-12-2753
16. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol (2014) 15(8):852-61. doi:10.1016/S1470-2045(14)70228-1
17. Ledermann JA, Perren PJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relaposed platinum sensitive ovarian cancer: results of the ICON6 trial. Presented at the 38th Congress of the European Society for Medical Oncology (ESMO) (2013).
18. Kummar S, Gutierrez ME, Chen A, Turkbey IB, Allen D, Horneffer YR, et al. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 47(7):997-1005. doi:10.1016/j.ejca.2010.12.016
19. Park SR, Speranza G, Piekarz R, Wright JJ, Kinders RJ, Wang L, et al. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas. Cancer Chemother Pharmacol (2013) 71(4):981-90. doi:10.1007/s00280-013-2091-3
20. Goodheart MJ, Vasef MA, Sood AK, Davis CS, Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol (2002) 86(1):85-90. doi:10.1006/gyno.2002.6730
21. Nadkarni NJ, Geest KD, Neff T, Young BD, Bender DP, Ahmed A, et al. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. Cancer Lett (2013) 331(1):99-104. doi:10.1016/j.canlet.2012.12.016
22. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, Chen S, et al. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem (2008) 80(12):4741-51. doi:10.1021/ac702628q
23. Kelly RJ, Rajan A, Force J, Lopez-Chavez A, Keen C, Cao L, et al. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 17(5):1190-9. doi:10.1158/1078-0432.CCR-10-2331
24. Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, et al. Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts. Clin Cancer Res (2008) 14(21):6877-85. doi:10.1158/1078-0432.CCR-08-0214
25. Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, et al. Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst (2014) 106(6):dju089. doi:10.1093/jnci/dju089
26. Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, et al. Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort. Mol Cell Proteomics (2013) 12(6):1621-31. doi:10.1074/mcp.M112.026427
27. Turkbey B, Thomasson D, Pang Y, Bernardo M, Choyke PL. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment. Diagn Interv Radiol (2010) 16(3):186-92. doi:10.4261/1305-3825.DIR.2537-08.1
28. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging (2003) 17(5):509-20. doi:10.1002/jmri.10304
29. Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia (2006) 8(2):79-88. doi:10.1593/neo.05592
30. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, et al. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol (2012) 23(4):919-27. doi:10.1093/annonc/mdr365
31. Mancuso P, Calleri A, Bertolini F. Circulating endothelial cells and circulating endothelial progenitors. Recent Results Cancer Res (2012) 195:163-70. doi:10.1007/978-3-642-28160-0_14
32. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 13(8):827-37. doi:10.1016/S1470-2045(12)70241-3
33. Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res (2010) 70(6):2171-9. doi:10.1158/0008-5472.CAN-09-2533
34. Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, et al. Changes in tumor blood flow as measured by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecol Oncol (2012) 126(3):375-80. doi:10.1016/j.ygyno.2012.06.002
35. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 28(12):2070-6. doi:10.1200/JCO.2009.25.4524
36. Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 11(3):261-2. doi:10.1038/nm1200
37. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res (2003) 9(1):377-82.
38. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, et al. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res (2005) 11(9):3514-22. doi:10.1158/1078-0432.CCR-04-2271
39. Monestiroli S, Mancuso P, Burlini A, Pruneri G, Dell'Agnola C, Gobbi A, et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res (2001) 61(11):4341-4.
40. Jacques N, Vimond N, Conforti R, Griscelli F, Lecluse Y, Laplanche A, et al. Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay. J Immunol Methods (2008) 337(2):132-43. doi:10.1016/j.jim.2008.07.006
41. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2010) 28(2):193-201. doi:10.1200/JCO.2009.22.4279
42. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res (2013) 19(24):6957-66. doi:10.1158/1078-0432.CCR-13-0926
43. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2012) 23(1):46-52. doi:10.1093/annonc/mdr047
44. Sanmamed MF, Carranza O, Alfaro C, Onate C, Martin-Algarra S, Perez G, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res (2014) 20(22):5697-707. doi:10.1158/1078-0432.CCR-13-3203
45. Singh JK, Simoes BM, Clarke RB, Bundred NJ. Targeting IL-8 signalling to inhibit breast cancer stem cell activity. Expert Opin Ther Targets (2013) 17(11):1235-41. doi:10.1517/14728222.2013.835398
46. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 100(5):359-72. doi:10.1093/jnci/djn024
47. Maccio A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications -a review. J Mol Med (Berl) (2013) 91(12):1355-68. doi:10.1007/s00109-013-1080-7
48. Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer (2014) 14:696. doi:10.1186/1471-2407-14-696
49. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 27(16):2705-11. doi:10.1200/JCO.2008.19.7681
50. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361(2):123-34. doi:10.1056/NEJMoa0900212
51. Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, et al. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 111(8):1269-80. doi:10.1111/j.1464-410X.2012.11667.x
52. Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, et al. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol (2014) 16(6):868-79. doi:10.1093/neuonc/nou040